Dupilumab versus swallowed fluticasone for narrowing (fibrostenotic) eosinophilic esophagitis
Comparative study of dupilumab and fluticasone in management of fibrostenotic Eosinophilic Esophagitis; a pilot and feasibility clinical trial.
This trial compares dupilumab injections with swallowed fluticasone in people who have fibrostenotic eosinophilic esophagitis to try to improve esophageal narrowing and swallowing symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11333745 on NIH RePORTER |
What this research studies
You would be randomly assigned to receive either dupilumab (a biologic injection) or swallowed topical fluticasone and then followed over time. Doctors will use endoscopy with EndoFLIP to measure esophageal distensibility (how well the esophagus stretches) and will collect patient-reported swallowing symptoms and quality-of-life measures. The study is a small pilot to test whether the trial procedures, measurements, and recruitment work before a larger trial. Researchers may also collect blood or tissue samples to learn about inflammation and scarring in the esophagus.
Who could benefit from this research
Good fit: People with fibrostenotic (narrowing or stiff) eosinophilic esophagitis who have ongoing swallowing problems and are candidates for biologic or topical steroid treatment would be the ideal participants.
Not a fit: People without fibrostenotic features, those whose swallowing problems are due to other conditions, or those unwilling to undergo injections or endoscopic testing may not receive benefit from this trial.
Why it matters
Potential benefit: If successful, this could identify which treatment better reduces esophageal narrowing and improves swallowing and quality of life for people with fibrostenotic EoE.
How similar studies have performed: Biologics such as dupilumab and swallowed topical steroids have both shown benefit in EoE, but direct head-to-head comparisons specifically in fibrostenotic EoE are novel.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Menard-Katcher, Calies D — University of Colorado Denver
- Study coordinator: Menard-Katcher, Calies D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.